The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements

Cancer Research

Volumn 64, Issue 12, 2004, Pages 4122-4130

  D'Amico, Mark ^a   Wu, Kongming ^a   Fu, Maofu ^a   Rao, Mahadev ^a   Albanese, Chris ^a   Russell, Robert G ^a   Lian, Hanzhou ^b   Bregman, David ^b   White, Michael A ^c   Pestell, Richard G ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4A; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN; PROTEIN P16INK4A; PROTEIN P19 ARF; PROTEIN P53; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL STRAIN MCF 7; CHROMATIN; CONTROLLED STUDY; DNA SEQUENCE; DNA SYNTHESIS; GENE FUNCTION; GENE LOCUS; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; PROMOTER REGIONS (GENETICS); REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 3042618740     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2519     Document Type: Article

References (75)

1. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
2. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270:23589-97.
3. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway Proc Natl Acad Sci USA 1999;96:5522-7.
4. Joyce D, Bouzahzah B, Fu M, et al. Integration of Rac-dependent regulation of cyclin D1 transcription through an NF-κB-dependent pathway. J Biol Chem 1999;274: 25245-9.
5. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond) 1994;369:669-71.
6. Lee RJ, Albanese C, Fu M, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
7. Zwijsen RML, Klompmaker R, Wientjens EBHGM, Kristel PMP, van der Burg B, Michalides RJAM. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol Cell Biol 1996;16:2554-60.
8. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond) 2001;411:1017-21.
9. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277:16464-9.
10. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006.
11. Albanese C, Wu K, D'Amico M, et al. IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 2003;14:585-99.
12. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-41.
13. Shivakumar L, Albanese C, Sakamaki T, Pestell RG, Minna J, White MA. The RASSF1A tumor suppressor negatively modulates cell cycle progression through inhibition of Cyclin D1 accumulation. Mol Cell Biol 2002;22:4309-18.
14. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 2002;22:5975-88.
15. Hendrik Gille H, Downward J. Multiple ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 1999;274:22033-40.
16. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
17. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998;12:2984-91.
18. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81: 323-30.
19. Serrano, M. The INK4a/ARF locus in murine tumorigenesis Carcinogenesis 2000; 21:865-9.
20. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9:22-30.
21. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo Genes Dev 1997;11:2822-34.
22. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998;12:3675-85.
23. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999;13:2670-7.
24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
25. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998;12:3008-19.
26. Zhu J, Woods D, McMahon M, Bishop J. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998;12:2997-3007.
27. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation EMBO J 2001;20:4912-22.
28. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998;95:8292-7.
29. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998;17:199-205.
30. Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol Cell Biol 2001;21:794-810.
31. Craig C, Kim M, Ohri E, et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 1998;16:265-72.
32. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash D C) 1994;264:436-40.
33. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/pI6/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
34. Hui R, Macmillan RD, Kenny FS, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000;6:2777-87.
35. Watanabe G, Howe A, Lee RJ, et al. Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci USA 1996;93:12861-6.
36. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature (Lond) 1995;375:503-6.
37. Ashton AW, Watanabe G, Albanese C, Harrington EO, Ware JA, Pestell RG. Protein kinase C delta inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1). J Biol Chem 1999;274:20805-11.
38. Albanese C, D'Amico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186-95.
39. Henry DO, Moskalenko SA, Kaur KJ, et al. Ra1 GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol 2000;20:8084-92.
40. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-7.
41. Albanese C, Reutens A, D'Amico M, et al. Sustained mammary gland directed ponasterone A-inducible expression in transgenic mice. FASEB J 2000;14:877-84.
42. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science (Wash D C) 1995;267:249-52.
43. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
44. Hatakeyama M, Brill JA, GR, F, Weinberg RA. Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev 1994;8:1759-71.
45. Hatakeyama M, Weinberg RA. The role of RB in cell cycle control. Prog Cell Cycle Res 1995;1:9-19.
46. Whyte P, Buchkovich KJ, Horowitz JM, et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (Lond) 1988;334:124-9.
47. Watanabe G, Lee RJ, Albanese C, Rainey WE, Batlle D, Pestell RG. Angiotensin II (AII) activation of cyclin D1-dependent kinase activity. J Biol Chem 1996;271: 22570-7.
48. Gadd M, Pisc C, Branda J, et al. Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution. Cancer Res 2001;61:8811-9.
49. D'Amico M, Wu K, Di Vizio D, et al. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res 2003;63:3395-402.
50. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59.
51. Kato K, Horiuchi S, Takahashi A, et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem 2002;277:11217-24.
52. Zhan Q, Chen IT, Antinore MJ, Fornace AJ, Fornace AJJ. Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding. Mol Cell Biol 1998;18:2768-78.
53. Prives C, Manley JL. Why is p53 acetylated? Cell 2001;107:815-8.
54. Motokura T, Arnold A. The PRAD1/Cyclin D1 proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 1993;7:89-95.
55. Lin A, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci USA 2001;98:5025-30.
56. Randle DH, Zindy F, Sherr CJ, Roussel MF. Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci USA 2001;98:9654-9.
57. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002;109:335-46.
58. Maloney KW, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999;93:2380-5.
59. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 1993;366:704-7.
60. Serizawa H. Cyclin-dependent kinase inhibitor p16INK4a inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH. J Biol Chem 1998;273: 5427-30.
61. Nishiwaki E, Turner SL, Harju S, et al. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation. Mol Cell Biol 2000;20:7726-34.
62. Watanabe G, Albanese C, Lee RJ, et al. Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol 1998;18:3212-22.
63. Koh J, Enders G, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature (Lond) 1995;375:506-10.
64. INK4a, TGFβ, and contact inhibition. Cell 1999;97:53-61.
65. v-src signaling in breast cancer cells. J Biol Chem 1999;274:7341-50.
66. Nakajima T, Uchida C, Anderson SF, et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 1997;90:1107-12.
67. Beier F, Lee RJ, Taylor AC, et al. Identification of the cyclin D1 gene as a target of ATF-2 in chondrocytes. Proc Natl Acad Sci USA 1999;96:1433-8.
68. Del Sal G, Murphy M, Ruaro EM, Lazarevic D, Levine AJ, Schneider C. Cyclin D1 and p21/waf1 are both involved in p53 growth suppression. Oncogene 1996;12:177-85.
69. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 2003;23:4713-27.
70. Kuo ML, Duncavage EJ, Mathew R, et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003;63:1046-53.
71. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
72. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
73. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001;15:2934-9.
74. Mitra J, Dai CY, Somasundaram K, et al. Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol 1999;19:3916-28.
75. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 1999;19:1981-9.